On Tuesday, Veracyte Inc (NASDAQ: VCYT) opened higher 6.65% from the last session, before settling in for the closing price of $36.71. Price fluctuations for VCYT have ranged from $18.61 to $41.43 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 34.42% over the past five years. Company’s average yearly earnings per share was noted 135.29% at the time writing. With a float of $76.31 million, this company’s outstanding shares have now reached $77.50 million.
Let’s look at the performance matrix of the company that is accounted for 815 employees. In terms of profitability, gross margin is 65.47%, operating margin of 2.6%, and the pretax margin is -1.92%.
Veracyte Inc (VCYT) Insider Updates
A key investor’s attitude towards the stock of the Diagnostics & Research industry is another important factor to consider. The insider ownership of Veracyte Inc is 1.54%, while institutional ownership is 106.22%. The most recent insider transaction that took place on Nov 19 ’24, was worth 540,775. Before that another transaction happened on Nov 12 ’24, when Company’s Chief Financial Officer sold 15,275 for $38.34, making the entire transaction worth $585,663. This insider now owns 124,501 shares in total.
Veracyte Inc (VCYT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 135.29% per share during the next fiscal year.
Veracyte Inc (NASDAQ: VCYT) Trading Performance Indicators
Check out the current performance indicators for Veracyte Inc (VCYT). In the past quarter, the stock posted a quick ratio of 4.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.13. Likewise, its price to free cash flow for the trailing twelve months is 53.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.14, a number that is poised to hit 0.11 in the next quarter and is forecasted to reach 0.60 in one year’s time.
Technical Analysis of Veracyte Inc (VCYT)
Veracyte Inc (NASDAQ: VCYT) saw its 5-day average volume 1.06 million, a positive change from its year-to-date volume of 0.77 million. As of the previous 9 days, the stock’s Stochastic %D was 35.43%. Additionally, its Average True Range was 1.76.
During the past 100 days, Veracyte Inc’s (VCYT) raw stochastic average was set at 89.49%, which indicates a significant increase from 71.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.19% in the past 14 days, which was lower than the 60.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.40, while its 200-day Moving Average is $26.18. Nevertheless, the first resistance level for the watch stands at $40.10 in the near term. At $41.05, the stock is likely to face the second major resistance level. The third major resistance level sits at $42.91. If the price goes on to break the first support level at $37.29, it is likely to go to the next support level at $35.43. Assuming the price breaks the second support level, the third support level stands at $34.48.
Veracyte Inc (NASDAQ: VCYT) Key Stats
There are currently 77,500K shares outstanding in the company with a market cap of 3.03 billion. Presently, the company’s annual sales total 361,050 K according to its annual income of -74,400 K. Last quarter, the company’s sales amounted to 115,860 K and its income totaled 15,160 K.
